



CeeTox Phase 1

Androgen receptor binding and
transcriptional activation in MDA
KB2 cells.

AD, delta-4-androstenedione (4-Androstene-3,17-dione)




MDA-kb2 AR luciferase reporter assay
AD



Solubility limit in medium: 1.0E-04


Cytotoxicity limit: 3.0E-05

MDA-kb2 AR luciferase reporter assay
AD
Antagonist Inhibition




Antagonist inhibition experiments were incubated in the presence of 0.01nM DHT.

CeeTox Phase 1 data for AD in MDA-kb2 assay
(from TopCount runs ending in 602,629,728)




CeeTox Phase 1 data for AD in MDA-kb2 assay
(from TopCount runs ending in 602,629,728)
Antagonist inhibition




AD in MDA KB2 ASSAY


LogEC50	-7.039
---------	--------




AD (delta 4 androstenedione) AR binding



DBP, dibutyl phthalate




**MDA-kb2 AR luciferase reporter assay
DBP**



Solubility limit in medium: 3.0E-04

Cytotoxicity limit: 1.0E-05


**MDA-kb2 AR luciferase reporter assay
DBP
Antagonist Inhibition**




Solubility limit in medium: 3.0E-04

Cytotoxicity limit: 1.0E-05


CeeTox Phase 1 data for DBP in MDA-kb2 assay
(from Top Count runs ending in 602,629)




CeeTox Phase 1 data for DBP in MDA-kb2 assay
(from TopCount runs ending in 629,728,803)
Antagonist inhibition




DBP (dibutyl phthalate) AR binding




DDE, p,p'-DDE (4,4'-DDE, p,p'-dichlorodiphenyldichlorethylene)



**MDA-kb2 AR luciferase reporter assay
DDE**




**MDA-kb2 AR luciferase reporter assay
p,p' DDE
Antagonist Inhibition**




Solubility limit in medium: 1.0E-05

Cytotoxicity limit: 3.0E-05


CeeTox Phase 1 data for DDE in MDA-kb2 assay
(from TopCount runs ending in 602,629)




CeeTox Phase 1 data for DDE in MDA-kb2 assay
(from TopCount runs ending in 629,728)
Antagonist inhibition




p,p' DDE in MDA KB2 plus DHT




DDE (p,p'-dichlorodiphenyldichlorethylene) AR binding



DHT, dihydrotestosterone, 5 α -androstano-17 β -ol-3-one




MDA-kb2 AR luciferase reporter assay
DHT




Solubility limit in medium: 3.0E-05

Cytotoxicity limit: 3.0E-05


DHT




DHT MKA KB2
AR agonism. LogEC50 -9.939




DHT (dihydrotestosterone) AR binding



LIN, Linuron




MDA-kb2 AR luciferase reporter assay LIN




Solubility limit in medium: 3.0E-05

Cytotoxicity limit: 3.0E-04


MDA-kb2 AR luciferase reporter assay LIN Antagonist Inhibition



CeeTox Phase 1 data for LIN in MDA-kb2 assay
(from TopCount runs ending in 602,629)




CeeTox Phase 1 data for LIN in MDA-kb2 assay
(from TopCount runs ending in 629,728)
Antagonist inhibition




Linuron plus DHT


LogEC50	-5.317
---------	--------




LIN (linuron) AR binding



PZ, prochloraz




MDA-kb2 AR luciferase reporter assay
PZ



Solubility limit in medium: 1.0E-04

Cytotoxicity limit: 1.0E-05


MDA-kb2 AR luciferase reporter assay
PZ




References:

Vinggaard, A.M., et.al. (2002) Toxicological Sciences 69, 344-353

CeeTox Phase 1 data for PZ in MDA-kb2 assay
(from TopCount runs ending in 602,629)




CeeTox Phase 1 data for PZ in MDA-kb2 assay
(from TopCount runs ending in 629,728)
Antagonist inhibition




Prochloraz plus DHT

LogEC50	-4.806
---------	--------




**Nigel's PZ data on AR antagonism in
MDA KB2 cells plus DHT**




PZ (prochloraz) AR binding



LogEC50	-4.393
---------	--------



Nigels AR binding with rat cytosol
LogEC50 -4.153




R1881 Metribolone, Methyltrienolone (17 β -Hydroxy-17 α -methyl-estra-4,9,11-trien-3-one)




Solubility limit in medium: 3.0E-05


Cytotoxicity limit: 3.0E-06




CeeTox Phase 1 data for R1881 in MDA-kb2 assay
(from TopCount runs ending in 728,803,810)




R1881 (Methyltrienolone) AR binding




TREN, trenbolone (17 β -Hydroxyestra-4,9,11-trien-3-one)



MDA-kb2 AR luciferase reporter assay
TREN




MDA-kb2 AR luciferase reporter assay
TREN



Solubility limit in medium: 1.0E-04


Cytotoxicity limit: 1.0E-05

CeeTox Phase 1 data for TREN in MDA-kb2 assay
(from TopCount runs ending in 803,810)




β Trenbolone


LogEC50	-9.808
---------	--------




TREN, (β -trenbolone) AR binding



VIN, vinclozolin




MDA-kb2 AR luciferase reporter assay
VIN



Solubility limit in medium: 1.0E-04

Cytotoxicity limit: 1.0E-05

MDA-kb2 AR luciferase reporter assay
VIN




References:


Grey, LE, et. al. (1999) Toxicology and Industrial Health 15: 48-64.

Wong et al. (1995) J Biol Chem. 270 (34): 19998.


CeeTox Phase 1 data for VIN in MDA-kb2 assay
(from TopCount runs ending in 713,803,810)




CeeTox Phase 1 data for VIN in MDA-kb2 assay
(from TopCount runs ending in 728,803,810)
Antagonist inhibition




Vinclozolin plus DHT



VIN (vinclozolin) AR binding




■ Iprodione △ Vinclozolin



	Iprodione AR binding	Vinclozolin
LogEC50	-4.066	-5.849

Data from Blystone et al., 2007


MDA-kb2 AR luciferase reporter assay
Flutamide: DHT Inhibition




CeeTox AR binding and transcriptional activation

- Phase 2


CdCl Fisher AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.15)




CdCl Fisher AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.15)




Anastrazole 120511-73-1
Compound 2 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Anastrazole 120511-73-1
Compound 2 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Atrazine (Aatrex) 1912-24-9
 Compound 3 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Atrazine (Aatrex) 1912-24-9
 Compound 3 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Bicalutamide 90357-06-5
Compound 4 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)



Bicalutamide 90357-06-5
Compound 4 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Bicalutamide 90357-06-5
AR Antagonism: LogEC50 -5.828




Compound 4 (Bicalutamide) AR binding


LogEC50 -6.820




Bisphenol A 80-05-7
Compound 5 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Bisphenol A 80-05-7
Compound 5 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Bisphenol A 80-05-7
AR Antagonism: LogEC50-4.864




Compound 5 (Bisphenol A) AR binding




Bisphenol B 77-40-7
 Compound 6 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Bisphenol B 77-40-7
 Compound 6 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.15)




Bisphenol B 77-40-7
AR Antagonism: LogEC50-4.997




Compound 6 (Bisphenol B) AR binding




2-sec butylphenol89-72-5
Compound 7 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




2-sec butylphenol89-72-5
Compound 7 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.21)



2-sec butylphenol 89-72-5
AR Antagonism: LogEC50 -6.061




Compound 7 (2-sec butylphenol) AR binding




TRICLOSAN


5-chloro-2-(2,4-dichlorophenoxy) phenol 3380-34-5
Compound 8 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07) cytotoxicity ↓ solubility limit ↓




5-chloro-2-(2,4-dichlorophenoxy) phenol 3380-34-5
Compound 8 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07) cytotoxicity ↓ solubility limit ↓




5-chloro-2-(2,4-dichlorophenoxy) phenol
3380-34-5 TRICLOSAN
AR Antagonism: LogEC50 -5.261




Compound 8 (5-chloro-2-(2,4-dichlorophenoxy) phenol)
AR binding




Clomiphene citrate 50-41-9
 Compound 9 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Clomiphene citrate 50-41-9
 Compound 9 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.15)




Corticosterone 50-22-6
Compound 10 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)



Corticosterone 50-22-6
Compound 10 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15)




Corticosterone 50-22-6
AR Induction: LogEC50 -5.596




Compound 10 (Corticosterone) AR binding
LogEC50 -5.628


LogEC50	-5.633
---------	--------




Coumestrol479-13-0
Compound 11 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)



Coumestrol479-13-0
Compound 11 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15, 12.21)




Coumestrol 479-13-0
AR Antagonism LogEC50 -6.070




Note: 2 of 3 logistic fits were “ambiguous”

Compound 11 (Coumestrol) AR binding


LogEC50	-5.328
---------	--------




4-Cumylphenol (phenol,
4-(1-methyl-1-phenylethyl))599-64-4
Compound 12 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)



4-Cumylphenol (phenol,
4-(1-methyl-1-phenylethyl))599-64-4
Compound 12 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




4-Cumylphenol (phenol, 4-(1-methyl-1-phenylethyl))
599-64-4. AR Antagonism: LogEC50 -5.030




Compound 12 (4-Cumylphenol) AR binding


LogEC50 -5.020




Cycloheximide66-81-9
 Compound 13 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Cycloheximide66-81-9
 Compound 13 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Cycloheximide 66-81-9
AR Antagonism: LogEC50 -5.616




Compound 13 (Cycloheximide) AR binding




Cyproterone acetate 427-51-0
Compound 14 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Cyproterone acetate 427-51-0
Compound 14 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Cyproterone acetate 427-51-0
AR Agonism: LogEC50 -5.933 (vs CA max)
and LogEC50 -5.000 vs DHT value




Cyproterone acetate 427-51-0
AR Antagonism: LogEC50 -6.268




Compound 14 (Cyproterone acetate) AR binding




Compound 14 (Cyproterone acetate) AR binding




Daidzein486-66-8
Compound 15 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Daidzein486-66-8
Compound 15 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.07, 12.21)




o,p'-DDT 789-02-6
Compound 16 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




o,p'-DDT 789-02-6
Compound 16 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.21)




o,p'-DDT 789-02-6
Compound 16 AR
AR Antagonism LogEC50 -4.833




Compound 16 (o,p'-DDT) AR binding




Dexamethasone 50-02-2
Compound 17 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07)




Dexamethasone 50-02-2
Compound 17 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07)




Dexamethasone 50-02-2
AR Agonism: LogEC50 -7.822




Compound 17 (Dexamethasone) AR binding




Dibenzo[a,h]anthracene 53-70-3
Compound 18 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Dibenzo[a,h]anthracene 53-70-3
Compound 18 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15)




Compound 18 (Dibenzo[a,h]anthracene) AR binding




Diethylhexyl phthalate [Bis(2-ethylhexyl) phthalate]
 117-81-7. Compound 19 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Diethylhexyl phthalate [Bis(2-ethylhexyl)
 phthalate] 117-81-7
 Compound 19 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.15)




Diethylhexyl phthalate
[Bis(2-ethylhexyl) phthalate]
CAS 117-81-7
Compound 19 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15)



Diethylstilbestrol 56-53-1
Compound 20 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Diethylstilbestrol 56-53-1
Compound 20 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15)




Luciferase interference at two highest conc compd 20


Dopamine 51-61-6 [62-31-7]
Compound 21 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Dopamine 51-61-6 [62-31-7]
Compound 21 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.21)




17 alpha-Estradiol 57-91-0
 Compound 22 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




17 alpha-Estradiol 57-91-0
 Compound 22 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.15)




17 alpha-Estradiol 57-91-0
AR Antagonism: LogEC50 -6.165




Compound 22 (17 α -Estradiol) AR binding




Estrone 53-16-7
Compound 23 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)



Estrone 53-16-7
Compound 23 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.21)




Estrone 53-16-7
AR Antagonism: LogEC50 -5.526




Compound 23 (Estrone) AR binding


LogEC50	-5.779
---------	--------




Fenarimol 60168-88-9
Compound 24 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Fenarimol 60168-88-9
Compound 24 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07, 12.21)



Flavone 525-82-6
Compound 25 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Flavone 525-82-6
Compound 25 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15, 12.21)




Luciferase interference at two highest conc compd 25


Flavone 525-82-6 Compound 25
AR Antagonism: LogEC_{50} -4.617




Compound 25 (Flavone) AR binding




Fluoranthene 206-44-0
Compound 26 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Fluoranthene 206-44-0
Compound 26 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Fluoranthene 206-44-0. Compound 26
AR Antagonism LogEC50 -5.083




Compound 26 (Fluoranthene) AR binding




Fluoxymestron 76-43-7
 Compound 27 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Fluoxymestron 76-43-7
 Compound 27 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Fluoxymestronone 76-43-7
AR Agonism: LogEC50 -8.484




Compound 27 (Fluoxymestron) AR binding




Flutamide 13311-84-7
Compound 28 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)



Flutamide 13311-84-7
Compound 28 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Flutamide 13311-84-7
AR Antagonism: LogEC50 -5.661




Note: the high conc in this figure was cytotoxic


Compound 28 (Flutamide) AR binding




Meso-Hexestrol (Hexestrol) 84-16-2
 Compound 29 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Meso-Hexestrol (Hexestrol) 84-16-2
 Compound 29 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.15)




Meso-Hexestrol (Hexestrol) 84-16-2
Compound 29
AR Antagonism LogEC50 -4.782




Compound 29 (Meso-Hexestrol) AR binding




Hydroxyflutamide 52806-53-8
Compound 30 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Hydroxyflutamide 52806-53-8
Compound 30 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15)




Hydroxyflutamide 52806-53-8
AR antagonism: LogEC50 -6.866




Compound 30 (Hydroxyflutamide) AR binding




4-Hydroxytamoxifen 68047-06-3
 Compound 31 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




4-Hydroxytamoxifen 68047-06-3
 Compound 31 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)



Kaempferol520-18-3
Compound 32 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15, 12.21)




Kaempferol520-18-3
Compound 32 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01 12.15)




Luciferase interference at two highest conc compd 32


Kepone (Chlordecone) 143-50-0
 Compound 33 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Kepone (Chlordecone) 143-50-0
 Compound 33 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Medroxyprogesterone acetate (6
alpha-Methyl-17alpha-hydroxyprogesterone
acetate) 71-58-9. Compound 34 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Medroxyprogesterone acetate
(6alpha-Methyl-17alpha-hydroxyprogesterone acetate)
71-58-9. Compound 34 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15, 12.21)




**Medroxyprogesterone acetate
(6alpha-Methyl-17alpha-hydroxyprogesterone acetate)
71-58-9. AR Agonism: LogEC50 -7.425**




Compound 34 (Medroxyprogesterone) AR binding




Methyl testosterone (17alpha-Methyltestosterone)
 58-18-4. Compound 35 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Methyl testosterone
 (17alpha-Methyltestosterone)
 Compound 35. AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




**Methyl testosterone
(17alpha-Methyltestosterone) 58-18-4
LogEC50 -9.231**




Compound 35 (Methyl testosterone) AR binding




Mifepristone 84371-65-3
 Compound 36 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Mifepristone 84371-65-3Compound 36
 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.15)




Mifepristone 84371-65-3
AR Partial Agonism:
LogEC50 -7.875 (vs Mif Max)
and LogEC50 -3.577 (vs DHT value)




Mifepristone 84371-65-3
AR Antagonism: LogEC50 -6.393




Compound 36 (Mifepristone) AR binding




4-nonylphenol 84852-15-3
Compound 37 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




4-nonylphenol 84852-15-3
Compound 37 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




4-nonylphenol 84852-15-3
Compound 37
AR Antagonism LogEC50 -5.063




Compound 37 (4-nonylphenol) AR binding




Nilutamide 63612-50-0
Compound 38 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Nilutamide 63612-50-0
Compound 38 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.15)




Nilutamide 63612-50-0
AR Antagonism: LogEC50 -6.918




Compound 38 (Nilutamide) AR binding




Norethynodrel 68-23-5
Compound 39 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.15)




Norethynodrel 68-23-5
Compound 39 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.15)




Norethynodrel 68-23-5
AR Agonism: LogEC50 -7.851




Compound 39 (Norethynodrel) AR binding




Neburon 555-37-3
Compound 40 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.15, 12.21)




Neburon 555-37-3
Compound 40 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.15, 12.15, 12.21)




Compound 40 (Neburon) AR binding




1-octadecanaminium,N,N,N-trimethyl-chloride
 (Trimethylstearylammmonium Chloride)
 112-03-8. Compound 41 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




1-octadecanaminium,N,N,N-trimethyl-chloride
 (Trimethylstearylammmonium Chloride) 112-03-8
 Compound 41 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01 12.15)




4-tert-Octylphenol 140-66-9
Compound 42 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




4-tert-Octylphenol 140-66-9
Compound 42 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




4-tert-Octylphenol 140-66-9
Compound 42
AR Antagonism LogEC50 -4.990




Compound 42 (4-tert-Octylphenol) AR binding




Oxazepam 604-75-1
 Compound 43 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07, 12.21)




Oxazepam 604-75-1
 Compound 43 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Oxazepam604-75-1
AR Antagonism: LogEC50 -4.788




Compound 43 (Oxazepam) AR binding




Procymidone 32809-16-8
Compound 44 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)




Procymidone 32809-16-8
Compound 44 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07, 12.21)




Procymidone 32809-16-8
LogEC50 -5.442




Compound 44 (Procymidone) AR binding




Progesterone 57-83-0
Compound 45 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Progesterone 57-83-0
Compound 45 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Progesterone 57-83-0
AR Agonism: LogEC50 -5.238 (vs P4 max)




Progesterone 57-83-0
AR Antagonism: LogEC50 -6.273




Compound 45 (Progesterone) AR binding




Spironolactone 52-01-7
Compound 46 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01 12.07, 12.15)




Spironolactone 52-01-7
Compound 46 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.07, 12.15)




Spirolactone 52-01-7
AR agonism :
Log EC50 -6.577 (vs Spir Max)
LogEC50 -4.941(vs DHT value)




Spirolactone 52-01-7
AR Antagonism: LogEC50 -6.844




Compound 46 (Spironolactone) AR binding




Testosterone 58-22-0
 Compound 47 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Testosterone 58-22-0
 Compound 47 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




Testosterone 58-22-0
AR Agonism: LogEC50 -9.216




Compound 47 (Testosterone) AR binding




12-O-Tetradecanoyl-phorbol-13-acetate
 (Phorbol 12-myristate) 16561-29-8
 Compound 48 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




12-O-Tetradecanoyl-phorbol-13-acetate
 (Phorbol 12-myristate) 16561-29-8
 Compound 48 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 12.01, 12.07, 12.15)




2,4,5-Trichloro-phenoxyacetic acid 93-76-5
Compound 49 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




2,4,5-Trichloro-phenoxyacetic acid
93-76-5
Compound 49 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)




Trimethylborate 121-43-7
Compound 50 AR Induction
CeeTox Phase-2 MDA-kb2 assay
(from 12.01, 12.07, 12.15)



Trimethylborate 121-43-7
Compound 50 AR Induction Antagonism
CeeTox Phase-2 MDA-kb2 assay
(from 12.07, 12.15)




Trimethylborate
CAS 121-43-7. Compound 50
CeeTox Phase-2 MDA-kb2 assay
(from 12.07, 12.15)
Cannot fit data to logistic regression




Compound 50 (Trimethylborate) AR binding


LogEC50 -2.778




Zearalenone 17924-92-4
 Compound 51 AR Induction
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Zearalenone 17924-92-4
 Compound 51 AR Induction Antagonism
 CeeTox Phase-2 MDA-kb2 assay
 (from 11.27, 12.07)




Zearalenone
CAS 17924-92-4, Compound 51
CeeTox Phase-2 MDA-kb2 assay
(from 11.27, 12.07)
LogEC50 -5.011




Compound 51 (Zearalenone) AR binding






Luciferase interference at two highest conc cmpd 1


Compound 1 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -4.750



Phase 3.
Compd 1: CAS 2634335,
1,2-benzisothiazoline-3-one

LogEC50	-3.260
---------	--------





Luciferase interference at two highest conc compd 2

5-Chloro-2-methyl-4-isothiazolin-3-one


26172-55-4

Compound 2 AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06)

LogEC50 -4.307




Phase 3. Compound 2
CAS 26172554
5-chloro-2-methyl-3(2H)-isothiazolone



4,5-dichloro-2-n-octyl-3(2H)-isothiazolone, (Kathon 930)

64359-81-5



Luciferase interference cmpd 3


4,5-dichloro-2-n-octyl-3(2H)-isothiazolone, (Kathon 930)


CAS 64359-81-5. Compound 3 AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay

(from 03.23, 03.30)


LogEC50 -4.658





Luciferase interference at highest conc cmpd 6


Phase 3. Compound 6
CAS 5915413 6-chloro-n(1,1-dimethylethyl)-
n`ethyl-1,3,5-triazine-2,4-diamine
LogEC50 -2.978



**2,4-imidazolidinedione,-1-(hydroxymethyl)-5,5-dimethyl;
(5,5-DIMETHYL-1-HYDROXYMETHYLHY - 5G&)**

116256

Compound 7 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)




2,4-imidazolidinedione,-1-(hydroxymethyl)-5,5-dimethyl

Compound 7

CeeTox Phase-3 MDA-kb2 assay


(from 03.02, 03.06)

LogEC50 -3.369



1-methoxy-4-tert-pentylcyclohexanol

Compound 10 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



1-methoxy-4-tert-pentylcyclohexanol


Compound 10

AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay


(from 03.10, 03.17)

LogEC50 -4.201



Phase 3. Compound 10
1-methoxy-4-tert-pentylcyclohexanol


LogEC50	-3.664
----------------	---------------




di-ethylphthalate (DEP)

84662

Compound 11 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.30)




Diethyl Phthalate CAS 84662
Compound 11 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.30) **LogEC50 -3.974**




Phase3. Compound 11
CAS 84662, Di-ethylphthalate


LogEC50	-3.625
---------	--------



di-n-hexylphthalate; (DIETHYL PHTHALATE PESTANAL)
CAS 84753. Compound 12
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06) Induction




Phase 3. Compound 12
CAS 84753, Di-n-hexylphthalate
LogEC50 -2.743




ethyl-2-methylbenzoate

87241


Compound 13 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)




ethyl-2-methylbenzoate
CAS 87241. Compound 13
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -2.967



Phase 3. Cmpd 13
CAS 87241, Ethyl-2-methylbenzoate
LogEC50 -2.792




ethoxyquin	91532
------------	-------




Luciferase interference at two highest conc compd 14

ethoxyquin
CAS 91532. Compound 14
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -4.380




Phase 3. Cmpd 14
CAS 91532, Ethoxyquin
LogEC50 -3.739




4-cyclohexylcyclohexanone

92682


Compound 15 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)



4-cyclohexylcyclohexanone
CAS 92682. Compound 15
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -5.318




Phase 3. Cmpd 15
CAS 92682
4-cyclohexylcyclohexanone
LogEC50 -4.207



tetrahydrofurfuryl alcohol ; (THF)

97994


Compound 16 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)



4-tert-butylcyclohexanol


98522

Compound 17 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)





+ luciferase interference

4-tert-butylcyclohexanol
CAS 98522. Compound 17
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -4.154



Compound 17. CAS 98522
4-tert-butylcyclohexanol
AR binding LogEC50 -3.369





Luciferase interference at two highest conc compd 18

N-dodecyltrimethylammonium chloride ; (DTA)


112005

Compound 18 AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06)

LogEC50 -5.563



Cmpd 18 . CAS 112005
N-dodecyltrimethylammonium chloride (DTA)
LogEC50 -3.200



Methylsalicylate


119368

Compound 19 AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay


(from 03.02, 03.06)

Induction




Luciferase interference at highest conc compd 19

methylsalicylate
CAS 119368. Compound 19
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -0.3609




Methylsalicylate
CAS. 119368 Cmpd 19
LogEC50 -2.394



propyl-3,4,5-trihydroxybenzoate; (PROPYL GALLATE); (PG)


121799

Compound 20 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



+++ luciferase interference

**propyl-3,4,5-trihydroxybenzoate;
(propyl gallate); (PG). Compound 20**
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -4.241



sodium 2-ethylhexylsulfate


126921

Compound 21 AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06)


Induction




di-isopropylphthalate ; (IPP)

605458


Compound 22 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)



di-isopropylphthalate; (IPP)
CAS 605458. Compound 22
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)
LogEC50 -4.217



Di-isopropylphthalate (DIPP)
CAS 605458. Cmpd 22
AR binding LogEC50 -3.266




4-tert-butylaniline


769926

Compound 23 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)


Induction



4-tert-butylaniline
CAS 769926
Compound 23
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -3.321



4-tert-butylaniline
CAS 769926. Cmpd 23
AR Binding. LogEC50 -3.331



ethyl-2,4,6-trimethylbenzoate


1754558

Compound 24 AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06)


Induction



ethyl-2,4,6-trimethylbenzoate
CAS 1754558. Compound 24
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -4.799



Ethyl-2,4,6-trimethylbenzoate
CAS 1754558. Cmpd 24
AR binding. LogEC50 -3.314




tert-butylhydroquinone

1948330

Compound 25 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay


(from 03.02, 03.06)

Induction




+ Luciferase interference at two highest conc compd 25

tert-butylhydroquinone
CAS 1948330. Compound 25
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -3.871



tert-butylhydroquinone
CAS 1948330. Cmpd 25
AR binding. LogEC50 -3.626




4-cyclohexylcyclohexanol; (CXC)

2433149

Compound 26 AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06, 04.05) Induction



4-cyclohexylcyclohexanol; (CXC)


CAS2433149. Compound 26

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06, 04.05)

LogEC50 -5.100



4-cyclohexylcyclohexanol (CXC)
CAS 2433149. Cmpd 26
AR binding LogEC50 -4.904



4-tert-amylcyclohexanol


5349519

Compound 27 AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06)


Induction



4-tert-amylcyclohexanol
CAS 5349519. Compound 27
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -4.955




4-tert-amylcyclohexanol
CAS 5349519. Cmpd 27
AR Binding LogEC50 -4.206




4-n-butylchlorobenzene

15499271


Compound 28 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)



4-n-butylchlorobenzene
CAS 15499271. Compound 28
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)
LogEC50 -2.469




4-n-butylchlorobenzene
CAS 15499271. Cmpd 28
AR Binding LogEC50 -2.446



2-tert-butyl-4-methoxyphenol
(2+3-TERT-BUTYL-4-METHOXYPHENOL, 98%) ; (TMOP)

25013165

Compound 29 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)



2-tert-butyl-4-methoxyphenol (TMOP)


CAS 25013165. Compound 29

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06)

LogEC50 -4.910




2-tert-butyl-4-methoxyphenol
CAS 25013165 Cmpd 29
AR Binding LogEC50 -3.871



4-n-amylniline (4-Pentylaniline); (AAN)

33228443

Compound 30 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.02, 03.06)



+ Luciferase interference at two highest conc compd 30

4-n-amylniline (4-Pentylaniline); (AAN)


CAS 33228443. Compound 30

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.02, 03.06)

LogEC50 -3.858




4-n-amyline
CAS 33228443 Cmpd 30
LogEC50 -3.523



4-hexylaniline; (HAL)


33228454

Compound 31 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



+ luciferase interference


4-hexylaniline ; (HAL)
Compound 31
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -3.800



4-propylcyclohexanone; (PCH)


40649363

Compound 32 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)




+ Luciferase interference at two highest conc compd 31

4-propylcyclohexanone; (PCH)
CAS 40649363. Compound 32
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)
LogEC50 -2.738




4-propylcyclohexanone
CAS 40649363 Cmpd 32
LogEC50 -2.665



3-methyl-4-chlorophenol; (4-CHLORO-3-METHYLPHENOL, 99%)

59507

Compound 33 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



3-methyl-4-chlorophenol; (4-CHLORO-3-METHYLPHENOL, 99%)


CAS 59507. Compound 33

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)

LogEC50 -4.418




3-methyl-4-chlorophenol
CAS 59507 Cmpd 33
LogEC50 -4.064



**4,4'-(1-methylethylidene)bis[2,6-dibromophenol],
(3,3',5,5'-Tetrabromobisphenol A)**

79947

Compound 34 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



**4,4'-(1-methylethylidene)bis[2,6-dibromophenol],
(3,3',5,5'-Tetrabromobisphenol A)**


CAS 79947. Compound 34

AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)


LogEC50 -5.140



4,4'-(1-methylethylidene)bis[2,6-dibromophenol]


CAS 79947 Cmpd 34

LogEC50 -5.547




benzoic acid, 2-hydroxy-, 4-(1,1-dimethylethyl)phenyl ester; (TBS)


87-18-3



Compound 36 AR Induction
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)




Compound 36 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)




+++ Luciferase interference at two highest conc cmpd 36

benzoic acid, 2-hydroxy-, 4-(1,1-dimethylethyl)phenyl ester; (TBS)


87-18-3



Compound 36 AR Induction
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)



Compound 36 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)




+++ Luciferase interference at two highest conc cmpd 36


phenol, 2,4-bis(1,1-dimethylethyl)-, (2,4-DI-TERT-BUTYLPHENOL)

96764

Compound 37 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)




phenol, 2,4-bis(1,1-dimethylethyl)-
Compound 37 AR Induction Antagonism
CeeTox Phase-3 (from 03.10, 03.17)
with cytotoxic dose LogEC50 -4.979,
without toxic dose LogEC50 -4.911



1,3-benzenediol, 4,4'-thiobis- ; (RES)

97290

Compound 38 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)



1,3-benzenediol, 4,4'-thiobis- ; (RES)


CAS 97290. Compound 38

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.17, 03.23)

LogEC50 -3.642




1,3-benzenediol, 4,4'-thiobis-
CAS 97290 Cmpd 38
LogEC50 -4.489



1-decanol, (DECYL ALCOHOL, 99+%) ; (DL) 112301

Compound 39 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 04.05)




1-decanol, (DECYL ALCOHOL) ; (DL)

Compound 39

CeeTox Phase-3 MDA-kb2 assay

(from 03.17, 04.05)


LogEC50 -3.989



10-undecenal (Undecylenic aldehyde)


112458

Compound 40 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)




phenyl salicylate	118558
-------------------	--------

Compound 41 AR Induction Antagonism
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.10, 03.17)




++ Luciferase interference at two highest conc compd 41

phenyl salicylate
CAS 118558. Compound 41
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -2.759




phenyl salicylate
CAS 118558 Cmpd 41
LogEC50 -2.495




benzyl salicylate ; (BES)	118581
---------------------------	--------

Compound 42 AR Induction Antagonism
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.10, 04.05)




+++ Luciferase interference at two highest conc compd 42

benzyl salicylate ; (BES)
CAS 118581. Compound 42
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 04.05)
LogEC50 -4.278




BenzyI salicylate
CAS 118581 Cmpd 42
LogEC50 -4.138




benzaldehyde, 3,4-dimethoxy-, (3,4-DIMETHOXYBENZALDEHYDE, 99%)

120149

Compound 43 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)




benzaldehyde, 3,4-dimethoxy-
Compound 43 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -2.220



phenol, 4-(phenylamino)-, (4-HYDROXYDIPHENYLAMINE)	122372
--	--------

Compound 44 AR Induction Antagonism
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.10, 03.17)



++ Luciferase interference at highest conc cmpd 44

phenol, 4-(phenylamino)-, (4-HYDROXYDIPHENYLAMINE)


CAS 122372. Compound 44

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)

LogEC50 -4.699




122372 phenol, 4-(phenylamino)-
Cmpd 44
LogEC50 -4.541



2-naphthol


135193

Compound 45 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)




+ Luciferase interference cmpd 45

2-naphthol
CAS 135193. Compound 45
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -4.248



2-naphthol
CAS 135193 Cmpd 45
LogEC50 -3.939





1,3-benzenedicarboxylic acid, diphenyl ester,
(DIPHENYL ISOPHTHALATE, 99%)

744456

Compound 46 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)


Induction




**1,3-benzenedicarboxylic acid, diphenyl ester,
(DIPHENYL ISOPHTHALATE, 99%)**

744456


Compound 46 AR Induction
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



Compound 46 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)




1,3-benzenedicarboxylic acid, diphenyl ester
CAS 744456 Cmpd46
LogEC50 -2.591




octyl aldehyde; octyltriethoxysilane	2943751
--------------------------------------	---------


Compound 47 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



octyl aldehyde; octyltriethoxysilane
CAS 2943751. Compound 47
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)




octyl aldehyde; octyltriethoxysilane
CAS 2943751 Cmpd 47
LogEC50 -2.389



Phenol, 4,4'-(9H-fluoren-9-ylidene)bis-;
4,4'-(9-Fluorenylidene)diphenol

3236713

Compound 48 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



+++ Luciferase interference at two highest conc cmpd 48


**sulcofuron-natrium monohydrate,
(SULCOFURON-SODIUM MONOHYDRATE)**

3567257

Compound 49 AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay

(from 03.17, 03.23) Induction



+++ Luciferase interference at two highest conc cmpd 49


sulcofuron-sodium monohydrate

Compound 49

CeeTox Phase-3 MDA-kb2 assay


(from 03.17, 03.23)

LogEC50 -4.055




Compound 50 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay


(from 03.17, 03.23) Induction



**2-naphthalenol, 6,6'-dithiobis- ;
6-Hydroxy-2-naphthyl disulfide
CAS 6088513. Compound 50**
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.17, 03.23)
LogEC50 -4.758




**2-naphthalenol, 6,6'-dithiobis-
CAS 6088513. Cmpd 50
AR antagonism. LogEC50 -4.549**




2-bromohexadecanoic acid	18263257
--------------------------	----------


Compound 51 AR Induction Antagonism
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.10, 03.17)



2-bromohexadecanoic acid
CAS 18263257. Compound 51
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -4.190



2-bromohexadecanoic acid
CAS 18263257 Cmpd 51
LogEC50 -4.939, Bottom -42.38




ethanone, 2,2-dimethoxy-1,2-diphenyl-

24650428

Compound 52 AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)




ethanone, 2,2-dimethoxy-1,2-diphenyl-
CAS 24650428. Compound 52

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)

LogEC50 -3.451




Ethanone, 2,2-dimethoxy-1,2-diphenyl-
CAS 24650428 Cmpd 52
LogEC50 -3.358




cis-3-hexenylsalicylate

65405-77-8




+++ Luciferase interference at two highest conc cmpd 53

cis-3-hexenylsalicylate
CAS 65405-77-8. Compound 53
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -4.322




cis-3-hexenylsalicylate
CAS 65405778 Cmpd 53
LogEC50 -3.508



peroxide, bis(1-methyl-1-phenylethyl)	80433
---------------------------------------	-------

Compound 54 AR Induction Antagonism
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.10, 03.17)



peroxide, bis(1-methyl-1-phenylethyl)


CAS 80433. Compound 54

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)

LogEC50 -4.792




peroxide, bis(1-methyl-1-phenylethyl)
CAS 80433 Cmpd 54
LogEC50 -3.842




1,3,5-triazine, 2,4,6-tris(2-propenyloxy)-

101371

Compound 55 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)



1,3,5-triazine, 2,4,6-tris(2-propenyloxy)-
CAS 101371. Compound 55
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.17)
LogEC50 -3.604



cyclotrisilazane, 2,2,4,4,6,6-hexamethyl-


1009934

Compound 56 AR Induction Antagonism

CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)

Induction



cyclotrisilazane, 2,2,4,4,6,6-hexamethyl-


CAS 1009934. Compound 56

AR Induction Antagonism


CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.17)

LogEC50 1.467




cyclotrisilazane, 2,2,4,4,6,6-hexamethyl-
CAS 1009934 Compound 56 AR binding
LogEC50 -1.861(1 of 3 curves converged)




benzeneethanol, .beta.-methyl-	1123859
--------------------------------	---------

Compound 57 AR Induction Antagonism
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.10)




benzeneethanol, .beta.-methyl-
Compound 57
CeeTox Phase-3 MDA-kb2 assay
(from 03.10)with cytotoxic conc **LogEC50 -1.811,**
without cytotoxic conc **LogEC50 -1.550**



methanone, phenyl(2,3,4-trihydroxyphenyl)-

1143722

Compound 58 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.10, 03.30)



++ Luciferase interference at two highest conc cmpd 58

methanone, phenyl(2,3,4-trihydroxyphenyl)-


Compound 58

CeeTox Phase-3 MDA-kb2 assay

(from 03.10, 03.30)

with cytotoxic conc LogEC50 -3.919


without cytotoxic conc LogEC50 -3.669



9,12-octadecadienoic acid (z,z)-, methyl ester

112630


Compound 59 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.23)




1-tetradecanamine, n,n-dimethyl-

112754


Compound 60 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.23)



1-tetradecanamine, n,n-dimethyl-
CAS 112754. Compound 60
AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.23)
LogEC50 -3.896




1-tetradecanamine, n,n-dimethyl-
CAS 112754 Cmpd 60
LogEC50 -0.4319 (1 of 2 curves converged)



octanal

124130


Compound 61 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.23)




phenol, 4,4'- 2,2,2-trifluoro-1-(trifluoromethyl)ethylidene bis-

1478611

Compound 62 AR Induction
CeeTox Phase-3 MDA-kb2 assay
(from 03.23)




Compound 62 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.23)



2,2,2-trifluoro-1-(trifluoromethyl)ethylidene bis-


Compound 62 AR Induction Antagonism
CeeTox Phase-3 MDA-kb2 assay
(from 03.23)




+++ Luciferase interference at highest conc cmpd 62

phenol, 4,4'- 2,2,2-trifluoro-1-(trifluoromethyl)ethylidene bis-
CAS 1478611 Compound 62


AR Induction Antagonism **LogEC50 -5.203**




phenol, 4,4'-2,2,2-trifluoro-1-(trifluoromethyl)ethylidene bis-
CAS 1478611. Cmpd 62
AR binding. LogEC50 -5.899



DHT AR Induction
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.06, 03.10, 03.17, 03.23, 03.30, 04.08)



DHT AR Induction Antagonism
 CeeTox Phase-3 MDA-kb2 assay
 (from 03.06, 03.10, 03.17, 03.23)



DHT
AR Induction
CeeTox Phase-3 MDA-kb2 assay
(from 03.06, 03.10, 03.17, 03.23, 03.30, 04.08)
LogEC50 -9.889
HillSlope 1.060

